Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome

Clinica Chimica Acta

Volumn 446, Issue , 2015, Pages 201-205

  Meneghel, Lauro ^a   Ruffatti, Amelia ^a   Gavasso, Sabrina ^a   Tonello, Marta ^a   Mattia, Elena ^a   Spiezia, Luca ^a   Tormene, Daniela ^a   Hoxha, Ariela ^a   Fedrigo, Marny ^a   Simioni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti Domain I antibodies; Anti 2 Glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid syndrome; Chemiluminescence immunoassay

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTI DOMAIN I BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; IMMUNOASSAY; IMMUNOLOGY; LUMINESCENCE; MIDDLE AGED; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; PROCEDURES; PROTEIN TERTIARY STRUCTURE; THROMBOSIS;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEIN STRUCTURE, TERTIARY; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 84929000742     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.04.033     Document Type: Article

References (39)

1. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Conti F., Capozzi A., Truglia S., et al. The mosaic of "seronegative" antiphospholipid syndrome. J Immunol Res 2014, 2014:1-7.
3. Hughes G.R., Khamashta M.A. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003, 62:1127.
4. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003, 102:2717-2723.
5. De Laat H.B., Derksen R.H., Urbanus R.T., Roest M., de Groot P.G. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004, 104:3598-3602.
6. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
7. George J., Gilburd B., Hojnik M., et al. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 1998, 160:3917-3923.
8. Arvieux J., Regnault V., Hachulla E., Darnige L., Roussel B., Bensa J.C. Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1998, 80:393-398.
9. Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998, 95:15542-15546.
10. McNeeley P.A., Dlott J.S., Furie R.A., et al. Beta2- glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001, 86:590-595.
11. De Laat B., de Groot P.G. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011, 13:70-76.
12. Iverson G.M., Reddel S., Victoria E.J., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002, 169:7097-7103.
13. Ioannou Y., Pericleous C., Giles I., Latchman D.S., Isenberg D.A., Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007, 56:280-290.
14. De Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005, 105:1540-1545.
15. De Laat B., Pengo V., Pabinger I., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7:1767-1773.
16. Banzato A., Pozzi N., Frasson R., et al. Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 2011, 128:583-586.
17. Ruffatti A., Tonello M., Del Ross T., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006, 96:337-341.
18. De Laat B., Derksen R.H., van Lummel M., Pennings M.T., de Groot P.G. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006, 107:1916-1924.
19. Pelkmans L., Kelchtermans H., de Groot P.G., et al. Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS One 2013, 8:1-9.
20. Chighizola C.B., Gerosa M., Meroni P.L. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014, 16:402-411.
21. Zhao L., Sun L., Chu X. Chemiluminescence immunoassay. Trends Anal Chem 2009, 28:404-414.
22. Roda A., Guardigli M. Analytical chemiluminescence and bioluminescence: latest achievements and new horizons. Anal Bioanal Chem 2012, 402:69-76.
23. Baeyens W.R., Schulman S.G., Calokerinos A.C., et al. Chemiluminescence-based detection: principles and analytical applications in flowing streams and in immunoassays. J Pharm Biomed Anal 1998, 17:941-953.
24. De Moerloose P., Reber G., Musial J., Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010, 8:1540-1546.
25. Persijn L., Decavele A.S., Schouwers S., Devreese K. Evaluation of a new set of automated chemiluminescence assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2011, 128:565-569.
26. Van Hoecke F., Persijn L., Decavele A.S., Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol 2012, 34:630-640.
27. Devreese K.M.J., Van Hoecke F. Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 2011, 128:598-600.
28. Devreese K.M.J., Pierangeli S.S., de Laat B., et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014, 12:792-795.
29. Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
30. Tincani A., Allegri F., Balestrieri G., et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004, 114:553-558.
31. Reber G., Tincani A., Sanmarco M., de Moerloose P., Boffa M.C. Proposals for the measurement of anti-b2-glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004, 2:1860-1862.
32. Ruffatti A., Olivieri S., Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008, 6:1693-1696.
33. Mondejar R., González-Rodríguez C., Toyos-Sáenz de Miera F.J., Melguizo-Madrid E., Zohoury N., Mahler M. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014, 431:174-178.
34. Devreese K., Kelchtermans H., de Laat B.J. Differences in sensitivity of two automated panels for anticardiolipin and anti-beta2glycoprotein I antibodies in the laboratory diagnosis of antiphospholipid syndrome due to the exposure of the domain I epitope of beta2glycoprotein I on the solid phase [abstract]. Thromb Haemost 2014, 12(S1):55.
35. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317.
36. Otomo K., Atsumi T., Amengual O., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012, 64:504-512.
37. Pengo V., Banzato A., Bison E., Bracco A., Denas G., Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?. Semin Thromb Hemost 2012, 38:322-327.
38. Ruffatti A., Tonello M., Visentin M.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011, 50:1684-1689.
39. Pengo V., Ruffatti A., Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid anti-body profile: a multicenter prospective study. Blood 2011, 118:4714-4718.